Newly-identified protein may contribute to colon cancer development
the ONA take:
A newly-identified pathway may contribute to the development of colon cancer, according to a study published in PLoS Genetics.
Researchers led by Anil Rustgi, MD, of the Perelman School of Medicine at the University of Pennsylvania conducted a follow-up to a 2013 study that identified the LIN28B protein as a contributor of cancerous growth in intestinal cells through suppression of Let-7 molecules.
In the new study, the researchers created transgenic mice that produced no Let-7 miRNAs in order to better understand their function in preventing cancer.
They found that adenomas adenomatous polyps, as well as adenocarcinomas that resembled human colon tumors, had formed in the intestines of all these mice without Let-7 by mid-adulthood.
Upon analyses of the tumors, they were able to identify a protein called Hmga2 as a major factor in their development. They were able to conclude that within the intestinal lining of the mice without Let-7, Hmga2 gene expression was unusually high.
In order to check the relevance of these findings, the researchers also examined several hundred human colorectal cancer samples and found lower-than-normal Let-7 miRNA as well as higher-than-normal HMGA2 (the human version of the mouse Hmga2 protein) expression.
A newly-identified pathway may contribute to the development of colon cancer.
Sign Up for Free e-newsletters
- Is Radioimmunotherapy a Path Forward for Melanoma?
- FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS
- ASCO Endorses SIO Guideline for Integrative Therapies in Breast Cancer
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- Seeking Reliable Information on Herbal Products
- Disparities Remain in Prevalence of Cancer Screening Tests
- Hope, Gratitude, and Spirituality: What They Mean to Cancer Patients
- FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma
- 8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers
- Combined Digital Screening Best for Detecting Breast Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|